Presentaciones
- Molecular landscape in NMIBC - Dr. Bishoy M. Faltas, Genitourinary Oncology Program in the Division of Hematology & Medical Oncology. Weill Cornell Medical College, New York. USA
- Intravesical alternatives for BCG unresponsive NMIBC - Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid
- The future of systemic therapy in NMIBC: what, when and how? - Dr. Bernadett Szabados, Urology Department, Barts Cancer Institute, London
- Updating New systemic treatment strategies for bladder preservation - Dr. Matthew Galsky, Genitourinary Medical Oncology, Mount Sinai Medical Center, New York. USA
- Current situation of bladder preservation approaches for MIBC: trimodal therapy and beyond - Dr. Óscar Rodríguez, Urology Department, Fundació Puigvert, Barcelona
- Adjuvant therapy: to whom and how - Dr. Teresa Alonso, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid
- Current landscape of second/third line therapy for mUC - Dr. María José Juan Fita, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia
- Biomarkers for mUrothelial Carcinoma. (nectin-4, Trop-2, HER2, FGFR) - Dr. Vadim S. Koshkin, Division of Hematology/Oncology, Department of Medicine University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA